Zimmer Biomet Stock Price, News & Analysis

Zimmer Biomet (NYSE: ZBH) has received FDA 510(k) clearance for its OsseoFit™ Stemless Shoulder System for total shoulder replacement. The innovative implant features an anatomically shaped design that matches natural humeral anatomy while preserving healthy bone. The system integrates with Identity® Humeral Heads and Alliance® Glenoid, offering versatile options for patient-specific needs.

Key features include left-or-right-sided anchor implants with fins for press-fit insertion, fully porous windows, and anterior reattachment suture holes. The system comes in a single instrument tray for efficient workflow. Commercial availability is scheduled for Q1 2025.

Zimmer Biomet (NYSE: ZBH) has received FDA 510(k) clearance for its Persona® SoluTion™ PPS® Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal. The implant features a porous coating for cementless fixation and a proprietary surface treatment for enhanced wear performance.

The device, when combined with Persona OsseoTi® Tibia and OsseoTi Patella, offers a fully cementless alternative to cobalt-chrome implants. Made of Tivanium® alloy, it minimizes common metal sensitizers and demonstrates similar wear performance compared to traditional cobalt chromium alloy components. Commercial availability in the U.S. is expected in Q1 2025.

Zimmer Biomet has received FDA approval for the Oxford® Cementless Partial Knee, making it the only cementless partial knee replacement implant available in the U.S. The approval is based on safety and effectiveness data from an IDE study. The device offers improved fixation, better long-term implant survival, and enhanced operating room efficiency compared to cemented procedures. With over 20 years of clinical experience and 300,000+ procedures worldwide, the implant features a mobile bearing design that mimics natural knee movement. The UK registry shows a 94.1% implant survival rate at 10 years, surpassing the average for other partial knees. U.S. launch is planned for Q1 2025.

Zimmer Biomet Holdings (NYSE and SIX: ZBH) has announced its participation in the upcoming Citi Global Healthcare Conference. The company's management team will engage in a fireside chat on December 5, 2024, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will be archived for future viewing after the conference concludes.

Zimmer Biomet (NYSE: ZBH) has received CE Mark certification for its Persona® Revision Knee System, expanding its availability in European markets. The system, which leads the $700+ million U.S. knee revision market, offers personalized solutions for revision knee arthroplasty. It features Trabecular Metal™ Technology for improved implant fixation and bone in-growth, along with modular components that enable surgeons to address complex cases with greater precision. The system's anatomic components and instrumentation are designed to streamline revision surgery while allowing intraoperative adjustments for optimal alignment and fit.

Zimmer Biomet (NYSE: ZBH) has announced a partnership with Arnold Schwarzenegger as their new Chief Movement Officer. In this strategic role, Schwarzenegger will work to motivate and support individuals in increasing mobility, maintaining joint health, and incorporating movement into daily routines. The partnership aligns with Zimmer Biomet's mission as a MedTech leader to alleviate pain and improve quality of life worldwide. Schwarzenegger, known for his 50-year fitness advocacy through various platforms including the Arnold Sports Festival and 'Arnold's Pump Club' newsletter, will collaborate with the company to promote active living and wellness initiatives.

Zimmer Biomet (NYSE and SIX: ZBH) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management team will engage in a fireside chat on November 19, 2024, at 11:00 a.m. GMT (6:00 a.m. ET). Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will be available for replay after the conference.

Zimmer Biomet (NYSE: ZBH) reported Q3 2024 financial results with net sales of $1.824 billion, representing a 4.0% increase year-over-year. The company achieved net earnings of $249.1 million, with diluted EPS of $1.23 and adjusted diluted EPS of $1.74. Notable developments include the planned launch of the Z1™ Femoral Hip System and acquisition of OrthoGrid Systems. However, due to ERP implementation challenges, the company has updated its 2024 guidance, reducing full-year revenue growth expectations to 3.5-4.0% from previous 4.0-5.0%, and narrowing adjusted EPS guidance to $7.95-$8.05 from $8.00-$8.15.

Zimmer Biomet announced the commercial launch of its new Z1™ Femoral Hip System at the 2024 AAHKS Annual Meeting. The Z1 System, featuring a triple-taper design, integrates with the company's G7® Acetabular System to provide a comprehensive hip arthroplasty solution. The system offers collared and collarless options, three distinct neck options, and uses a single streamlined instrument tray. The company also highlighted its recent acquisition of OrthoGrid Systems, adding AI-powered surgical assistance applications to its portfolio. Clinical data on the G7 Acetabular System's safety and durability will be presented at the meeting.